Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration

October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.

VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.

For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html